Rethinking Neoadjuvant Chemotherapy for breast cancer- Prof Jayant Vaidya
Original BMJ paper is available at https://www.bmj.com/content/360/bmj.j...
Full paper is available at http://discovery.ucl.ac.uk/10041365/
Full paper + Discussion is available at http://bit.ly/nactbmj2018full
The BMJ Podcast https://soundcloud.com/bmjpodcasts/ne...
Key messages
Neoadjuvant chemotherapy is being increasingly used for breast cancer despite higher rates of local recurrence and no evidence of survival benefit, mainly because of the immediate and dramatic pathological responses seen with newer drugs
The increased pathological response of the primary tumour in the breast does not translate into a survival benefit even when given in the adjuvant setting, challenging the paradigm of “window of opportunity” studies
We must acknowledge that neoadjuvant chemotherapy may not be beneficial to breast cancer patients
We should consider reducing the widespread use of neoadjuvant chemotherapy
